Contact us: +91 9550333722 040 - 40102781
Structured search
India
Choose your country
Different countries will display different contents
Try our best to find the right business for you.
My chemicalbook

Welcome back!

HomeProduct name listSumatriptan succinate

Sumatriptan succinate

Synonym(s):3-[2-(Dimethylamino)ethyl]-N-methyl-1H-indole-5-methanesulfonamide succinate;GR-43175;Sumatriptan succinate

  • CAS NO.:103628-48-4
  • Empirical Formula: C18H27N3O6S
  • Molecular Weight: 413.48848
  • MDL number: MFCD00902856
  • EINECS: 600-463-4
  • SAFETY DATA SHEET (SDS)
  • Update Date: 2024-11-19 20:33:22
Sumatriptan succinate Structural

What is Sumatriptan succinate?

Description

Sumatriptan succinate is a highly selective 5HT1-like receptor agonist introduced as a new treatment for migraine. It is indicated for the acute relief of migraine and cluster headache. Oral administration is reported to be free of substantial side effects. The compound appears to be a significant advance over the use of ergotamine and other agents in the treatment of migraine.

Chemical properties

White Crystalline Powder

Originator

Glaxo (United Kingdom)

The Uses of Sumatriptan succinate

Sumatriptan Succinate is a selective 5-HT1B/1D-receptor agonist with anticonvulsant properties (1,2). Sumatriptan Succinate is used for migraine relief (2).

The Uses of Sumatriptan succinate

Sumatriptan (succinate) is a serotonin 5-hydroxytryptamine 1 (5-HT1) receptor agonist with selective affinity for 5-HT1B and 5-HT1D receptors with IC50 values of 9.3 and 7.3 nM, respectively. It also has affinity for the 5-HT1F receptor (IC50 = 17.8 nM). Sumatriptan (succinate) has been shown to induce vasoconstriction of human middle meningeal arteries (EC50 = 89.9 nM) and reduce vascular inflammation associated with migraines.

Definition

ChEBI: A succinate salt obtained by reaction of sumatriptan with one equivalent of succinic acid. Selective agonist for a vascular 5-HT1 receptor subtype (probably a member of the 5-HT1D family). Used for the acute treatm nt of migraine with or without aura in adults.

Manufacturing Process

A solution of (phenylthio)acetaldehyde (6.05 g) in absolute ethanol (180 ml) was added over 10 min to a solution of 4-hydrazino-Nmethylbenzenemethanesulphonamide hydrochloride (10 g) in water (180 ml) with cooling. After addition of the aldehyde was complete, the mixture was stirred at 5°C for a period of 14 h. The precipitated solid was filtered off, washed with water (200 ml), hexane (200 ml) and dried in vacuo to give the N-methyl-4-[2-[2-(phenylthio)ethylidene]hydrazino]benzenemethanesulphonamide (10.95 g), melting point 110°-112°C.
A solution of the N-methyl-4-[2-[2- (phenylthio)ethylidene]hydrazino]benzenemethane-sulphonamide in absolute ethanol (300 ml) was saturated with hydrogen chloride gas (ca. 30 min) whilst being cooled in an ice-water bath, allowed to stir at room temperature for 3 h and filtered. The filtrate was concentrated in vacuo and chromatographed to afford a foam, which solidified on trituration with ether to an amorphous powder (2.17 g). A sample was recrystallized from hexane-dichloromethane to give the N-methyl-3-(phenylthio)-1H-indole-5-methanesulphonamide, melting point 133°-134°C.
To a solution of N-methyl-3-(phenylthio)-1H-indole-5-methanesulphonamide (460 mg) in absolute ethanol (50 ml) was added Raney nickel [4.6 g, 50% slurry in water, washed to neutrality with deionized water (60 ml)] and the reaction mixture refluxed for 16 h under an atmosphere of nitrogen. On cooling to room temperature, the supernatant was removed and the Raney nickel extracted with ethanol (2x50 ml, which was brought to a gentle reflux for 15 min under an atmosphere of nitrogen). The combined extracts were filtered through a sand-celite pad and concentrated in vacuo. Chromatography of the residue, afforded an oil (87 mg) which crystallized from ether-hexane to give the N-methyl-1H-indole-5-methanesulphonamide (90 mg), melting point 127°-129°C.
To N,N-diethyl chloroacetamide (800 mg) at 0°C was added phosphorous oxychloride (250 μl) over a period of 30 sec. After the addition was complete, the mixture was allowed to stir at 0°C for 15 min and then at room temperature for 20 min. The N-methyl-1H-indole-5-methanesulphonamide (300 mg) was added at 0°C and the mixture warmed to 65°C, whereupon it dissolved. The mixture was stirred for 2 h at this temperature then poured onto ice (ca. 5 g) and chloroform (5 ml) and stirred vigorously for 1 h. A solid was filtered off, washed with water (50 ml), and hexane (100 ml) and dried in vacuo to give the 3-(chloroacetyl)-N-methyl-1H-indole-5- methanesulphonamide (192 mg).
A solution of the 3-(chloroacetyl)-N-methyl-1H-indole-5- methanesulphonamide (160 mg) in ethanolic dimethylamine (30 ml, 33% w/v solution in ethanol) was heated to reflux for 2 h. On cooling to room temperature the solvent was removed in vacuo and the residue was chromatographed to afford the 3-[(dimethylamino)acetyl]-N-methyl-1Hindole- 5-methanesulphonamide, melting point 230°C, dec.
To a suspension of the 3-[(dimethylamino)acetyl]-N-methyl-1H-indole-5- methanesulphonamide (46.5 mg) in 1-propanol (5 ml) was added sodium borohydride (62 mg). The reaction mixture was brought to reflux for a period of 3 h, then an additional quantity of borohydride (60 mg) was added. After refluxing for a further 1 h, the mixture was allowed to cool to room temperature and quenched with 2 N HCl (10 ml). The aqueous solution was washed with ethyl acetate (5 ml) then neutralized (NaHCO3 solution) and extracted with ethyl acetate (3 x 15 ml). The combined extracts were concentrated in vacuo and the residue chromatographed to give the 3-[2- (dimethylamino)ethyl]-N-methyl 1H-indole-5-methanesulphonamide as a gum (2 mg) which was shown by TLC.
Succinic acid in hot methanol was added to a hot solution of the the 3-[2- (dimethylamino)ethyl]-N-methyl-1H-indole-5-methanesulphonamide in absolute ethanol and the mixture was heated to reflux with stirring to give a solution. The solution was allowed to cool with stirring to room temperature, and the resultant suspension was farther cooled in an ice-bath for 2 h. The solid was filtered off, washed with ethanol, and dried in vacuo to give the 3- [2-(dimethylamino)ethyl]-N-methyl-1H-indole-5-methanesulphonamide, salt with succinic acid (1:1).

brand name

Imitrex (GlaxoSmithKline);Imigran.

Therapeutic Function

Serotoninergic

World Health Organization (WHO)

Suprofen, a nonsteroidal anti-inflammatory agent, was introduced in 1983 for use as an analgesic for the symptomatic relief of mild to moderate pain and for primary dysmenorrhoea. By 1986 it had become evident that its use was occasionally associated with flank pain sometimes accompanied by evidence of decreased renal function. The Arthritis Advisory Committee of the United States Food and Drug Administration met in December 1986 to review the situation and decided against withdrawing suprofen from the market. However, in May 1987 the Committee for Proprietary Medicinal Products of the European Community recommended that all marketing authorizations should be suspended. The manufacturer subsequently decided to suspend sale worldwide on the grounds that sales had diminished to the point where the product was no longer economically viable.

Biological Activity

Selective 5-HT 1 receptor agonist (K i values are 17, 27 and 100 nM at 5-HT 1D , 5-HT 1B and 5-HT 1A receptors respectively). Antimigraine agent.

Biochem/physiol Actions

Sumatriptan succinate is a 5-HT1 serotonin receptor agonist.

storage

+4°C

Properties of Sumatriptan succinate

Melting point: 165-166°C
storage temp.  -20°C
solubility  H2O: >20mg/mL
form  solid
color  white to off-white
Merck  14,8997
CAS DataBase Reference 103628-48-4(CAS DataBase Reference)

Safety information for Sumatriptan succinate

Signal word Warning
Pictogram(s)
ghs
Health Hazard
GHS08
GHS Hazard Statements H412:Hazardous to the aquatic environment, long-term hazard
Precautionary Statement Codes P202:Do not handle until all safety precautions have been read and understood.
P273:Avoid release to the environment.
P280:Wear protective gloves/protective clothing/eye protection/face protection.
P308+P313:IF exposed or concerned: Get medical advice/attention.
P405:Store locked up.
P501:Dispose of contents/container to..…

Computed Descriptors for Sumatriptan succinate

InChIKey PORMUFZNYQJOEI-UHFFFAOYSA-N

Abamectin manufacturer

Urantiis Pharmaceuticals Private Limited

2Y
Phone:+91-8790703567
Whatsapp: +91- 8790703567
product: [3-[2-(Dimethyl amino) ethyl]-1H-indol-5-yl]-N-methyl methane sulphonamide (Sumatriptan Base) 103628-48-4 99
Inquiry

Aurobindo Pharma Limited

1Y
Phone:+91-4066725000
product: Sumatriptan Succinate 103628-48-4 98%
Inquiry

Smilax Laboratories Limited

1Y
Phone:+918008333438
Whatsapp: +91-8008333438
product: 103628-48-4 Sumatriptan Succinate 98%
Inquiry

Sun Pharmaceutical Industries Ltd

1Y
Phone:+912243244324
product: 103628-48-4 98%
Inquiry

Nosch Labs Pvt Ltd

1Y
Phone:+91-9948222287
product: Sumatriptan Succinate 99%
Inquiry

Orchid Pharma Ltd. (Formerly Known as Orchid Chemicals and Pharmaceuticals Ltd.)

1Y
Phone:+91-4428244254
product: Sumatriptan Succinate 103628-48-4 99%
Inquiry

Lakshmi Farmachem

1Y
Phone:+91-9550886476
Whatsapp: +91-9550886476
product: Sumatriptan Succinate 98%
Inquiry

Stereokem Pvt Ltd

1Y
Phone:+919394224843
Whatsapp: +91-9394224843
product: Sumatriptan Succinate 98%
Inquiry

HRV Global Life Sciences

1Y
Phone:+91-9820219686
Whatsapp: +91 9820219686
product: Sumatriptan Succinate 99%
Inquiry

Related products of tetrahydrofuran

You may like

  • [3-[2-(Dimethyl amino) ethyl]-1H-indol-5-yl]-N-methyl methane sulphonamide (Sumatriptan Base) 103628-48-4 99
    [3-[2-(Dimethyl amino) ethyl]-1H-indol-5-yl]-N-methyl methane sulphonamide (Sumatriptan Base) 103628-48-4 99
    103628-48-4
    View Details
  • 103628-48-4 Sumatriptan Succinate 98%
    103628-48-4 Sumatriptan Succinate 98%
    103628-48-4
    View Details
  • 103628-48-4 Sumatriptan Succinate 98%
    103628-48-4 Sumatriptan Succinate 98%
    103628-48-4
    View Details
  • Sumatriptan Succinate CAS 103628-48-4
    Sumatriptan Succinate CAS 103628-48-4
    103628-48-4
    View Details
  • Sumatriptan Succinate 98%
    Sumatriptan Succinate 98%
    View Details
  • Sumatriptan Succinate 98%
    Sumatriptan Succinate 98%
    View Details
  • Sumatriptan succinate >98% (HPLC) CAS 103628-48-4
    Sumatriptan succinate >98% (HPLC) CAS 103628-48-4
    103628-48-4
    View Details
  • Sumatriptan succinate 95.00% CAS 103628-48-4
    Sumatriptan succinate 95.00% CAS 103628-48-4
    103628-48-4
    View Details
Statement: All products displayed on this website are only used for non medical purposes such as industrial applications or scientific research, and cannot be used for clinical diagnosis or treatment of humans or animals. They are not medicinal or edible.